The report highlights Genmab's commitment to sustainable, socially responsible business practices and key accomplishments for the year, including the launch of their first approved medicine, Tivdak®, co-developed with Seagen, the FDA granting Priority Review of their investigational bispecific antibody epcoritamab for the treatment of patients with relapsed/refractory LBCL, and their dedication to furthering patient engagement and integrating sustainability into their strategic planning and risk management processes.
Issuing Company Genmab A/S
Report Type Sustainability Report
Report Language EN
Report Filesize 7.15 MB
No. of Pages 49 pages
Reporting periodJanuary 1-December 31, 2022
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs; others
Materiality Assessmenttrue
